FDA WARNING_LETTER - HA Stores, Ltd
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
The FDA issued a Warning Letter to HA Stores, Ltd. for offering unapproved new drugs and misbranded drugs for sale on multiple websites, including healthymedz.com.ru and rx-easymeds.com. The products violate sections 301(a), 301(d), 503(b), and 505(a) of the FD&C Act.
Specifically, "Roxicontin" (Roxicodone) is marketed as a narcotic pain reliever without FDA approval, despite FDA-approved Roxicodone bearing a black box warning for serious risks like addiction and respiratory depression. "Slimall (Meridia)," marketed for obesity, is also unapproved; Meridia was voluntarily withdrawn from the U.S. market in 2010 due to increased risks of heart attack and stroke.
These products are considered misbranded under section 502(f)(1) because they lack adequate directions for safe use by a layperson, as they are prescription drugs. The FDA emphasizes the particular concern regarding Roxicodone due to the opioid abuse epidemic.
HA Stores, Ltd. must immediately cease marketing these violative drug products. Failure to correct these violations may result in regulatory actions such as seizure or injunction. A written response detailing corrective actions is required within 10 working days.
- Company
- HA Stores, Ltd
- Product Type
- Drugs
ID · 55cd3c00-5854-4a39-a978-ae297afc189e
Full citation text and observation details available on the Dashboard.